Hep C - Lipid Sciences, Inc. Receives Conditional Approval From the FDA of Investigational Device Exemption (IDE) Application

Lipid Sciences, Inc. Receives Conditional Approval From the FDA of Investigational Device Exemption (IDE) Application
[Press Release] Market Wire via Yahoo! Finance - Jan 31 5:30 AM
Lipid Sciences, Inc. today reported that it had received conditional approval for the Company's Investigational Device Exemption application from the Center for Devices and Radiological Health of the Food and Drug Administration to begin a human clinical trial of the Company's Plasma Delipidation System-2.Save to My Web

Migenix: infectious ambitions in hepatitis
Pharmaceutical Business Review - Jan 25 6:07 PM
Migenix has confirmed plans to initiate a viral kinetics study with celgosivir in hepatitis C.Save to My Web

Transgene Receives Grant for Hepatitis C Vaccine
RedNova - Jan 26 9:14 PM
France-based biopharmaceutical company Transgene has been awarded an E1.3 million for the development of its therapeutic vaccine candidate against hepatitis C chronic infection.Save to My Web

He's a fighter
News Gleaner - Feb 01 12:09 PM
Six years ago, Wissinoming resident John Waddell gave hope to Philadelphia firefighters who had just learned they were infected with the Hepatitis C virus.Save to My Web

Nabi Biopharmaceuticals Announces U.S. Fast Track Designation for Civacir to Prevent Hepatitis C Re-infection in Liver
[Press Release] PR Newswire via Yahoo! Finance - Feb 01 4:15 PM
Nabi Biopharmaceuticals today announced important regulatory and clinical advancements for its product candidate Civacir [Hepatitis C Immune Globulin ], an antibody for preventing Hepatitis C virus re-infection in liver transplants.Save to My Web